Key Insights

Highlights

Success Rate

61% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

16.9%

11 terminated out of 65 trials

Success Rate

60.7%

-25.8% vs benchmark

Late-Stage Pipeline

9%

6 trials in Phase 3/4

Results Transparency

53%

9 of 17 completed with results

Key Signals

9 with results61% success11 terminated

Data Visualizations

Phase Distribution

50Total
Not Applicable (7)
Early P 1 (3)
P 1 (14)
P 2 (20)
P 3 (6)

Trial Status

Completed17
Recruiting14
Terminated11
Unknown8
Withdrawn5
Active Not Recruiting5

Trial Success Rate

60.7%

Benchmark: 86.5%

Based on 17 completed trials

Clinical Trials (65)

Showing 20 of 20 trials
NCT03796273Early Phase 1Terminated

Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases

NCT03180502Phase 2Active Not Recruiting

Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma

NCT07712757Phase 3Not Yet Recruiting

Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma

NCT04623931Phase 2Recruiting

Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas

NCT07703436Phase 2Not Yet Recruiting

Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease

NCT05303519Phase 3Recruiting

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

NCT07673705Completed

GliomaAI-Oligo: MRI-Based Detection of IDH Mutant Oligodendroglioma

NCT03900689Completed

Social Determinants of Health in Glioblastoma Population

NCT06161974Phase 2Recruiting

Study of Olutasidenib and Temozolomide in HGG

NCT04105374Phase 2Withdrawn

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

NCT05190172Not ApplicableRecruitingPrimary

PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas

NCT05513859Not ApplicableSuspended

Investigational Imaging Technique During Brain Surgery

NCT05484622Phase 1Active Not Recruiting

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

NCT03152318Phase 1Active Not Recruiting

A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2

NCT07439172Phase 2Not Yet Recruiting

Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.

NCT05345002Phase 2Recruiting

All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

NCT05331521Phase 3RecruitingPrimary

A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).

NCT04702581Phase 3RecruitingPrimary

A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery

NCT07031765Phase 1Active Not Recruiting

Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma

NCT04541082Phase 1Recruiting

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Scroll to load more

Research Network

Activity Timeline